Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.09
NAS:ENDP's Cash to Debt is ranked lower than
54% of the 1152 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.37 vs. NAS:ENDP: 0.09 )
NAS:ENDP' s 10-Year Cash to Debt Range
Min: 0.09   Max: No Debt
Current: 0.09

Equity to Asset 0.22
NAS:ENDP's Equity to Asset is ranked lower than
53% of the 1034 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.58 vs. NAS:ENDP: 0.22 )
NAS:ENDP' s 10-Year Equity to Asset Range
Min: 0.08   Max: 0.76
Current: 0.22

0.08
0.76
F-Score: 4
Z-Score: 1.10
M-Score: -2.07
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) -31.17
NAS:ENDP's Operating margin (%) is ranked higher than
51% of the 1102 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.84 vs. NAS:ENDP: -31.17 )
NAS:ENDP' s 10-Year Operating margin (%) Range
Min: -31.17   Max: 38.19
Current: -31.17

-31.17
38.19
Net-margin (%) -25.07
NAS:ENDP's Net-margin (%) is ranked higher than
51% of the 1102 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.10 vs. NAS:ENDP: -25.07 )
NAS:ENDP' s 10-Year Net-margin (%) Range
Min: -79.44   Max: 24.67
Current: -25.07

-79.44
24.67
ROE (%) -32.30
NAS:ENDP's ROE (%) is ranked higher than
51% of the 1129 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.93 vs. NAS:ENDP: -32.30 )
NAS:ENDP' s 10-Year ROE (%) Range
Min: -113.34   Max: 26.98
Current: -32.3

-113.34
26.98
ROA (%) -7.58
NAS:ENDP's ROA (%) is ranked higher than
55% of the 1161 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.32 vs. NAS:ENDP: -7.58 )
NAS:ENDP' s 10-Year ROA (%) Range
Min: -39.34   Max: 17.45
Current: -7.58

-39.34
17.45
ROC (Joel Greenblatt) (%) -138.67
NAS:ENDP's ROC (Joel Greenblatt) (%) is ranked higher than
51% of the 1156 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.14 vs. NAS:ENDP: -138.67 )
NAS:ENDP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -116.32   Max: 753.26
Current: -138.67

-116.32
753.26
Revenue Growth (3Y)(%) -4.60
NAS:ENDP's Revenue Growth (3Y)(%) is ranked higher than
58% of the 932 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. NAS:ENDP: -4.60 )
NAS:ENDP' s 10-Year Revenue Growth (3Y)(%) Range
Min: -4.6   Max: 30.3
Current: -4.6

-4.6
30.3
» NAS:ENDP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

ENDP Guru Trades in Q1 2014

George Soros 198,503 sh (New)
Larry Robbins 1,964,201 sh (New)
Paul Tudor Jones 3,506 sh (New)
Louis Moore Bacon 5,602 sh (New)
Julian Robertson 22,800 sh (New)
Steven Cohen 271,917 sh (+1456.75%)
Wallace Weitz 500,920 sh (+12.33%)
John Griffin 8,000,000 sh (unchged)
John Griffin 676,600 sh (unchged)
John Griffin 8,000,000 sh (unchged)
Jeremy Grantham Sold Out
Ray Dalio Sold Out
Joel Greenblatt Sold Out
David Dreman Sold Out
Stanley Druckenmiller Sold Out
Steve Mandel 4,178,703 sh (-3.72%)
Mario Gabelli 30,550 sh (-8.40%)
Jana Partners 2,563,215 sh (-11.53%)
Jim Simons 49,493 sh (-95.08%)
» More
Q2 2014

ENDP Guru Trades in Q2 2014

Chuck Royce 1,300 sh (New)
Joel Greenblatt 88,697 sh (New)
Paul Tudor Jones 177,373 sh (+4959.13%)
Louis Moore Bacon 15,334 sh (+173.72%)
Larry Robbins 3,930,472 sh (+100.11%)
Wallace Weitz 876,670 sh (+75.01%)
Jana Partners 3,199,017 sh (+24.80%)
Julian Robertson 22,800 sh (unchged)
John Griffin 6,766 sh (unchged)
George Soros Sold Out
Jim Simons Sold Out
Steve Mandel Sold Out
John Griffin 6,815,000 sh (-14.81%)
Mario Gabelli 23,900 sh (-21.77%)
» More
Q3 2014

ENDP Guru Trades in Q3 2014

Larry Robbins 5,658,326 sh (+43.96%)
John Griffin 676,600 sh (unchged)
Chuck Royce Sold Out
Louis Moore Bacon Sold Out
Jana Partners Sold Out
Mario Gabelli 22,900 sh (-4.18%)
Julian Robertson 20,300 sh (-10.96%)
John Griffin 5,698,528 sh (-16.38%)
Wallace Weitz 721,950 sh (-17.65%)
Joel Greenblatt 13,716 sh (-84.54%)
Paul Tudor Jones 19,281 sh (-89.13%)
» More
Q4 2014

ENDP Guru Trades in Q4 2014

RS Investment Management 351,943 sh (New)
Pioneer Investments 389,510 sh (New)
George Soros 1,748,729 sh (New)
Larry Robbins 6,851,326 sh (+21.08%)
Wallace Weitz 767,530 sh (+6.31%)
John Griffin 676,600 sh (unchged)
Julian Robertson Sold Out
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
Mario Gabelli 19,900 sh (-13.10%)
John Griffin 4,409,000 sh (-22.63%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:ENDP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Endo International PLC

Larry Robbins Lives Up to Reputation for Investing in Healthcare Sector
During the campaigns in the recently concluded midterm elections, incumbent Democrats were reluctant to speak of Obamacare, almost as hesitant as they were to be seen with the president, on the campaign trail. Read more...

Ratios

vs
industry
vs
history
Forward P/E 18.59
ENDP's Forward P/E is ranked higher than
87% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. ENDP: 18.59 )
N/A
P/B 6.10
ENDP's P/B is ranked higher than
55% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.13 vs. ENDP: 6.10 )
ENDP' s 10-Year P/B Range
Min: 1.48   Max: 17.5
Current: 6.1

1.48
17.5
P/S 4.76
ENDP's P/S is ranked higher than
53% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.19 vs. ENDP: 4.76 )
ENDP' s 10-Year P/S Range
Min: 1.03   Max: 6.1
Current: 4.76

1.03
6.1
PFCF 75.20
ENDP's PFCF is ranked higher than
76% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. ENDP: 75.20 )
ENDP' s 10-Year PFCF Range
Min: 4.6   Max: 264.07
Current: 75.2

4.6
264.07
POCF 51.49
ENDP's POCF is ranked higher than
74% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 45.91 vs. ENDP: 51.49 )
ENDP' s 10-Year POCF Range
Min: 3.96   Max: 90.18
Current: 51.49

3.96
90.18
Current Ratio 1.07
ENDP's Current Ratio is ranked higher than
50% of the 1100 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.13 vs. ENDP: 1.07 )
ENDP' s 10-Year Current Ratio Range
Min: 1.07   Max: 3.06
Current: 1.07

1.07
3.06
Quick Ratio 0.91
ENDP's Quick Ratio is ranked higher than
55% of the 1100 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.60 vs. ENDP: 0.91 )
ENDP' s 10-Year Quick Ratio Range
Min: 0.91   Max: 2.88
Current: 0.91

0.91
2.88
Days Inventory 116.84
ENDP's Days Inventory is ranked higher than
76% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 148.81 vs. ENDP: 116.84 )
ENDP' s 10-Year Days Inventory Range
Min: 66.62   Max: 157.75
Current: 116.84

66.62
157.75
Days Sales Outstanding 156.64
ENDP's Days Sales Outstanding is ranked higher than
60% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 89.68 vs. ENDP: 156.64 )
ENDP' s 10-Year Days Sales Outstanding Range
Min: 62.07   Max: 164.01
Current: 156.64

62.07
164.01

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 2.20
ENDP's Price/DCF (Projected) is ranked higher than
89% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. ENDP: 2.20 )
ENDP' s 10-Year Price/DCF (Projected) Range
Min: 0.4   Max: 1.97
Current: 2.2

0.4
1.97
Price/Median PS Value 1.70
ENDP's Price/Median PS Value is ranked higher than
65% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.60 vs. ENDP: 1.70 )
ENDP' s 10-Year Price/Median PS Value Range
Min: 0.4   Max: 1.77
Current: 1.7

0.4
1.77
Price/Peter Lynch Fair Value 81.10
ENDP's Price/Peter Lynch Fair Value is ranked higher than
87% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. ENDP: 81.10 )
ENDP' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.47   Max: 1.08
Current: 81.1

0.47
1.08
Earnings Yield (Greenblatt) -4.30
ENDP's Earnings Yield (Greenblatt) is ranked lower than
51% of the 1148 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. ENDP: -4.30 )
ENDP' s 10-Year Earnings Yield (Greenblatt) Range
Min: -4.3   Max: 25.4
Current: -4.3

-4.3
25.4
Forward Rate of Return (Yacktman) 17.85
ENDP's Forward Rate of Return (Yacktman) is ranked higher than
84% of the 576 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.03 vs. ENDP: 17.85 )
ENDP' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 3.3   Max: 63.3
Current: 17.85

3.3
63.3

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:EO7.Germany, ENL.Canada,
Endo International PLC was incorporated in Ireland on October 31, 2013. It is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products as well as medical devices. Its current portfolio is associated with a set of therapeutic areas including, Allergy Immunotherapy, Central Precocious Puberty, Dermatology, Insomnia, Pain, Pelvic Health, Urology and Women's Health.
» More Articles for ENDP

Headlines

Articles On GuruFocus.com
Weitz Value Fund First Quarter 2015 Commentary Apr 20 2015 
Weekly Insider Sells Highlight: ANTM, ENDP, QVCA, TOL Apr 12 2015 
Valeant Finally Bags Salix for $11 Billion Apr 06 2015 
This Week’s Pharma Highlights Mar 19 2015 
Valeant Pharmaceuticals Goes Aggressive To Win Over Salix Mar 18 2015 
Valeant Pharma Acquires Salix Mar 18 2015 
Endo International Shares Upbeat After Positive Q4 Earnings Report Mar 03 2015 
Valeant Pharmaceuticals Finally Zeros In On Salix Pharmaceuticals Feb 24 2015 
George Soros' Top New Holdings Feb 18 2015 
Three Pharma Majors In The Run To Acquire Salix Feb 16 2015 


More From Other Websites
Endo International, a New Position for OZ Management Apr 24 2015
DepoMed Set To Grow On 'Transformative' Nucynta Deal Apr 23 2015
Shire Gets Dropped from AQR Capital’s Portfolio Apr 23 2015
Will the Salix-Valeant story play out over and over again? Apr 23 2015
Meet Pharma’s Newest Movers and Shakers Apr 22 2015
Lone Pine Reduces Its Stake in Valeant Pharmaceuticals Apr 22 2015
Morgan Stanley US drug sector note predicts 'no M&S slowdown' Apr 21 2015
OZ Management’s New Positions in 4Q14 Apr 20 2015
Autohome, Other Foreign Stock Leaders Seen Posting Big Q1 Apr 13 2015
Permian Investment Partners Has A Thing or Two To Teach You About Investing Apr 10 2015
Endo International plc (ENDP), BioMarin Pharmaceutical Inc. (BMRN): Visium Picks Returned 13% but... Apr 10 2015
Tiger Ratan Trumps Hedge Fund Industry in Q1; See How Nehal Chopra’s Stock Picks Performed Apr 10 2015
Billionaire John Griffin’s Five Picks That Killed the Market This Quarter Apr 09 2015
What's Next For The Thousands Of Angry Men Suing Over Testosterone? Apr 06 2015
3 JPMorgan Bull Calls Hitting The Market Apr 02 2015
These 10 Pharma and Health Care Stocks Were the Best S&P 500 Performers Last Quarter Apr 02 2015
Drugmaker Valeant completes $11 billion purchase of Salix Apr 01 2015
Valeant closes $11B deal for Raleigh's Salix Pharmaceuticals Apr 01 2015
BioDelivery Slumps, Diabetic Pain Gel Fails Phase III Study - Analyst Blog Mar 31 2015
Can Boston Scientific Keep Its Turnaround Gains Going? Mar 30 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK